NYSE:ORCL

Oracle Corporation's (NYSE:ORCL) Recent Developments and Stock Performance

Font: Financial Modeling Prep  • Feb 14, 2026

Market Chart
  • Oracle Corporation (NYSE:ORCL) faces a securities fraud lawsuit, potentially affecting its stock performance.
  • CEO Magouyrk Clayton M. sold 10,000 shares, raising questions about the company's internal affairs.
  • The stock price shows a 2.34% increase today, despite ongoing legal proceedings and market volatility.

Oracle Corporation (NYSE:ORCL) is a leading technology company known for its software products and services, including database management systems and cloud solutions. The company competes with other tech giants like Microsoft and SAP. Recently, Oracle has been in the spotlight due to a securities fraud lawsuit, urging shareholders who have faced financial losses to contact the law firm Glancy Prongay Wolke & Rotter LLP.

The lawsuit suggests potential issues within Oracle that may have affected its stock performance. On February 9, 2026, Oracle's CEO, Magouyrk Clayton M., sold 10,000 shares at approximately $155.23 each. This transaction might raise questions among investors about the company's internal affairs, especially since the CEO still holds 134,030 shares.

Despite these concerns, Oracle's stock is currently priced at $160.14, showing a 2.34% increase today, equivalent to a $3.66 rise. The stock has fluctuated between $155.29 and $162.06 during the trading day. This volatility might reflect investor reactions to the ongoing legal proceedings and recent executive stock sales.

Oracle's market capitalization is approximately $460.26 billion, indicating its significant presence in the tech industry. The stock's trading volume today is 17.91 million shares, suggesting active investor interest. Over the past year, Oracle's stock has seen a high of $345.72 and a low of $118.86, highlighting its fluctuating market performance.

Shareholders are encouraged to stay informed about the lawsuit and Oracle's stock movements. The legal proceedings and executive transactions could impact investor confidence and the company's future stock performance.

Market Overview
BRTX
BioRestorative Therapies, Inc.
$0.27
18.41%
SGN
Signing Day Sports, Inc.
$0.79
46.11%
LGVN
Longeveron Inc.
$1.08
103.02%
DXST
Decent Holding Inc.
$0.38
42.72%
NIO
NIO Inc.
$5.45
10.32%
VTAK
Catheter Precision, Inc.
$1.94
41.61%
HIMS
Hims & Hers Health, Inc.
$23.93
7.99%
HIMZ
Daily Target 2X Long HIMS ETF
$2.35
15.76%
RENX
RenX Enterprises Corp.
$0.13
-4.83%
NVDA
NVIDIA Corporation
$183.96
0.72%